The short answer
Thyroid cancer survival varies enormously by subtype, far more than most cancers. Using SEER data, the American Cancer Society reports overall five-year relative survival above 99% for papillary thyroid cancer, 98% for follicular, 93% for medullary, and only about 10% for anaplastic thyroid cancer.
A survival statistic describes a large group diagnosed years ago — not a prediction for any one person.
Thyroid cancer subtype (papillary, follicular, medullary, or anaplastic) matters more than any single overall statistic.
Papillary and follicular thyroid cancer generally have an excellent outlook; anaplastic thyroid cancer is rare but aggressive.
Even within a favorable subtype, stage at diagnosis still affects outlook.
Choose how you want to understand this
The full explanation.
Before you look at the numbers
Three things are true about the numbers below. Please read all three before you look at a single thyroid cancer percentage.
First, a "5-year relative survival rate" for thyroid cancer describes a large group of people. Those people were diagnosed with thyroid cancer years ago. It is not a prediction about you. Everyone's thyroid cancer, body, and treatment plan are different.
Second, this data lags behind today's care. The subtype figures below come from the American Cancer Society, and they reflect people diagnosed between 2015 and 2021. Thyroid cancer treatment has continued to change since then, especially for advanced or anaplastic disease. So thyroid cancer treatment today may already work better than these numbers suggest.
Third, an all-stages thyroid cancer number blends two very different groups. It mixes people whose thyroid cancer was found early. It also counts people whose thyroid cancer had already spread. For thyroid cancer, the stage-specific numbers below beat one blended average. And "5-year" is just a measuring window, not a thyroid cancer milestone. It is not a life expectancy for anyone with thyroid cancer. It is not a deadline either.
The SEER numbers for thyroid cancer
Thyroid cancer is not one disease statistically. The American Cancer Society uses SEER data for people diagnosed between 2015 and 2021. It reports overall five-year relative survival above 99% for papillary thyroid cancer, the most common type. The figure is 98% for follicular thyroid cancer and 93% for medullary thyroid cancer. For anaplastic thyroid cancer, which is rare and aggressive, it is about 10%.
Survival by stage also differs sharply between subtypes. Distant-stage disease, for example, is 71% for papillary but only 5% for anaplastic thyroid cancer.
NCI's own SEER Stat Facts page does not split thyroid cancer by subtype. It treats it as one disease, based on people diagnosed between 2016 and 2022, and gives five-year relative survival of 98.3% across all stages. By that count 63% of thyroid cancers are found while still confined to the thyroid, where survival is 99.9%. Another 31% have reached nearby lymph nodes, at 98.1%. Only 3% are found after spread to distant organs, and there it is 48.3%.
| Stage at diagnosis | 5-year relative survival |
|---|---|
| Papillary — all stages combined | >99% |
| Follicular — all stages combined | 98% |
| Medullary — all stages combined | 93% |
| Anaplastic — all stages combined | 10% |
What "relative survival" actually means
Relative survival compares two groups. One group has thyroid cancer. The other group is the same age and sex, but has no thyroid cancer. Say the rate is 100%. That would mean the thyroid cancer group was as likely to reach 5 years as the other. It is not the share of people who are free of thyroid cancer. It is not the share of people who die from thyroid cancer itself.
Thyroid cancer subtype matters so much that an overall thyroid cancer statistic is close to meaningless on its own. Papillary and follicular thyroid cancers are usually slow-growing and highly treatable. Medullary thyroid cancer behaves differently. It is sometimes linked to inherited genetic syndromes. Anaplastic thyroid cancer is rare, but it grows and spreads quickly and needs urgent treatment.
What actually changes your outlook
A statistic describes a group. Your outlook depends on things specific to you.
- Stage — how far the thyroid cancer has spread, as shown in the table above.
- Grade — how odd the thyroid cancer cells look, and how fast they tend to grow.
- Histologic subtype — papillary, follicular, medullary, and anaplastic thyroid cancers have very different outlooks.
- Genetic testing — mutations such as BRAF or RET, and inherited syndromes linked to medullary thyroid cancer, can affect treatment.
- How your thyroid cancer responds — early scans and labs often say more than the first numbers.
- Your overall health — other health problems, age, and fitness shape thyroid cancer treatment and recovery.
- Access to care — a quick thyroid cancer diagnosis, specialist care, and finishing treatment all matter.
Questions for your care team
- Which SEER stage describes my thyroid cancer, and what is its five-year number?
- Which biomarkers or molecular tests matter in thyroid cancer, and were they run on my sample?
- How do my age and overall health change these thyroid cancer statistics for me?
- Are there newer thyroid cancer treatments available now that this data doesn't reflect yet?
- Beyond the general thyroid cancer statistics, what does my team expect in my case?
- Where can I find support for how it feels to hear these thyroid cancer numbers?
- Which subtype of thyroid cancer do I have, and what does that mean for my expected course and follow-up?
If these numbers are hard to sit with
Thyroid cancer numbers can leave you scared, numb, or overwhelmed. That is normal. It does not mean you are handling a thyroid cancer diagnosis the wrong way. Many people take these thyroid cancer numbers in slowly, or with someone in the room. Others skip the numbers until they feel ready. Cancer Anxiety and Uncertainty covers the fear these thyroid cancer numbers can stir up. It is also worth telling your thyroid cancer team how much detail you want, and when.
Sources
Words to know
Tap any term to see what it means.
Common questions
What does 'five-year relative survival' mean when it varies so much by subtype?
It means the standard measurement (comparing a group of patients to people the same age and sex without cancer) still applies, but thyroid cancer must be broken out by subtype for the number to mean anything. A single blended thyroid cancer statistic would hide huge real differences.
Why is survival so much lower for distant-stage disease even in 'good' subtypes?
Even papillary thyroid cancer, which has an excellent overall outlook, has lower survival once it reaches the distant stage (71% versus over 99% for earlier stages). Stage still matters within each subtype, even though subtype matters more than stage overall.
Does this number predict what will happen to me?
No. This is a statistic about a large group of people, not a prediction about you. Your specific subtype, age, overall health, and how your thyroid cancer responds to treatment all shape your individual outlook.
Is this the most current data available?
It is the most recent subtype-level data available. The American Cancer Society has not yet moved these figures on, so they still cover people diagnosed between 2015 and 2021. NCI's own SEER Stat Facts page, which reports thyroid cancer as one disease rather than by subtype, is now based on people diagnosed between 2016 and 2022. Treatment, especially for advanced or anaplastic thyroid cancer, keeps changing.
Why doesn't this page give one single thyroid cancer survival number?
Because it would be misleading. Thyroid cancer subtypes behave so differently from each other that a single blended number hides more than it reveals. Knowing your specific subtype is the single most useful piece of information for understanding your outlook.
I've heard thyroid cancer is 'the good cancer' — is that fair?
Not always. Most thyroid cancer, especially papillary and follicular subtypes, has an excellent outlook, which is where that phrase comes from. But it isn't true for everyone. Anaplastic thyroid cancer is aggressive, and even common subtypes still require real treatment, monitoring, and often lifelong follow-up.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Speak With Trained Specialists & Human Navigators
Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.
Talk to a trained cancer information specialist
Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.
Contact your oncology team
Locate after-hours contact numbers, portal messages, or urgent triage phone lines.
Find a patient navigator
Get one-on-one help with appointments, logistics, translation, and care coordination.
Find a genetic counselor
Discuss inherited mutation risk, family history, and genetic testing options.
Find an oncology social worker
Access emotional counseling, family support groups, and mental health resources.
Find a financial navigator
Locate copay assistance foundations, grant programs, and lodging/travel support.
Find a clinical-trial specialist
Search matching studies and speak with NCI trial information specialists.
Get urgent help
Immediate emergency guidance for fever (>100.4°F during chemo), severe pain, or shortness of breath.
Help Us Improve This Guide
Did this explanation answer your question and help you determine your next step?
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Plain-language explanation of the published sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.
Last updated: 2026-08-19Next planned review: 2027-08-03
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status — Source checked. This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
High-risk topic — talk to your care team. This topic can involve urgent, individual medical decisions. This page is general education only: it cannot tell you whether your situation is an emergency or what you personally should do. Follow your oncology team's instructions and contact them for individual guidance.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status: Source checked — This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
Read more about our editorial process, our use of AI, and our corrections policy.
Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.
After using this page, do you understand what to do next?
Anonymous — we only record the answer, never who gave it.
Related articles
Still have questions?
Educational answers, plain language
Free to print and share